These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19046556)

  • 21. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
    Kovács G; Pötter R; Loch T; Hammer J; Kolkman-Deurloo IK; de la Rosette JJ; Bertermann H
    Radiother Oncol; 2005 Feb; 74(2):137-48. PubMed ID: 15734201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.
    ; Frank SJ; Arterbery VE; Hsu IC; Abdel-Wahab M; Ciezki JP; Hahn NM; Mohler JL; Moran BJ; Rosenthal SA; Rossi CJ; Yamada Y; Merrick G
    Brachytherapy; 2011; 10(5):357-62. PubMed ID: 21497562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
    Lilleby W; Tafjord G; Raabe NK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer.
    Hurwitz MD
    Nat Clin Pract Oncol; 2008 Nov; 5(11):668-76. PubMed ID: 18825143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In regard to Anagnostopoulos et al.: In vivo thermoluminescence dosimetry dose verification of transperinal (192)Ir high dose rate brachytherapy using CT-based planning for the treatment of prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:1183-1191).
    Duggan L; Bucci J; Kron T
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):911; author reply 911-2. PubMed ID: 15183495
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
    Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT
    J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid state TL detectors for in vivo dosimetry in brachytherapy.
    Gambarini G; Borroni M; Grisotto S; Maucione A; Cerrotta A; Fallai C; Carrara M
    Appl Radiat Isot; 2012 Dec; 71 Suppl():48-51. PubMed ID: 22920417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
    Hirokawa Y
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.